Mistletoe therapy, a form of integrative oncology, is gaining traction worldwide due to its promising role in cancer management. Rooted in decades of research, mistletoe extracts (Viscum album) are used as complementary treatments alongside chemotherapy, radiation, or surgery to improve patients’ quality of life and potentially enhance therapeutic outcomes.
ABNOBA GmbH, a renowned German pharmaceutical company based in Pforzheim, has been a pioneer in producing high-quality, research-based mistletoe preparations. These products are standardized for active compounds such as mistletoe lectins, which are believed to play a central role in stimulating the immune system and inducing cancer cell apoptosis.
Numerous clinical and laboratory studies have supported the use of mistletoe therapy in oncology. Research has shown that it may reduce treatment-related fatigue, nausea, and emotional distress. In some trials, patients treated with mistletoe extract demonstrated improved tolerance to chemotherapy and reported better overall well-being.
While mistletoe therapy is not a substitute for conventional treatments, its complementary use is widely accepted in several European countries, particularly in Germany and Switzerland. Its effects on immune modulation and tumor suppression continue to be areas of active scientific investigation.
ABNOBA India is dedicated to bringing this integrative approach to Indian patients by offering access to ABNOBA’s scientifically validated formulations. By supporting ongoing education and research, ABNOBA India aims to empower clinicians and patients with safe, evidence-based options for enhancing cancer care.
